Pharmacogenomics and Medication Development for Methamphetamine Dependence

甲基苯丙胺依赖的药物基因组学和药物开发

基本信息

批准号：
8039262
负责人：
Keith Gregory Heinzerling
金额：
$ 16.97万
依托单位：
UNIVERSITY OF CALIFORNIA LOS ANGELES
依托单位国家：
美国
项目类别：
财政年份：
2008
资助国家：
美国
起止时间：
2008-04-01 至 2013-03-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8039262
关键词：
Address Area Award Bupropion CYP2B6 gene Clinical Clinical Investigator Clinical Markers Clinical Trials Clinical Trials Cooperative Group Cognitive Therapy Criminal Justice DNA DRD2 gene Data Development Disease Enrollment Female Frequencies Funding Future Genes Genetic Genetic Markers Genetic Polymorphism Genomics Genotype Goals HIV Infections Healthcare Systems K-Series Research Career Programs Medicine Mentored Patient-Oriented Research Career Development Award Mentorship Metabolism Methamphetamine Methamphetamine dependence Methodology Molecular National Institute of Drug Abuse Neurobiology Outcome Participant Pathogenesis Patients Pharmaceutical Preparations Pharmacogenomics Pharmacotherapy Placebos Psychotic Disorders Public Health Randomized Recruitment Activity Research Research Infrastructure Research Personnel Resources Sampling Screening procedure Secure Series Severities Specimen Subgroup Substance abuse problem Training Translational Research Translations United States addiction base cellular targeting clinical phenotype clinical practice contingency management effective therapy experience insight male novel psychosocial randomized placebo controlled trial randomized trial repository response responsible research conduct stimulant abuse treatment response

项目摘要

DESCRIPTION (provided by applicant): Methamphetamine (MA) use is the fastest growing drug problem in the United States, placing strain on the criminal justice and health care systems and resulting in significant public health consequences, including HIV infection. Understanding of the neurobiological, molecular, and cellular basis of MA dependence has increased, yet no medications effective for MA dependence are available. Pharmacogenomic studies have the potential to accelerate the translation of neurobiological findings into safe and effective pharmacotherapies for MA dependence by identifying genes associated with clinical phenotypes of MA dependence and response to treatment. The goal of this Mentored Patient-Oriented Research Career Development Award is to provide Keith Heinzerling, MD, MPH with the training and experience needed to become an independent clinical investigator in the area of pharmacogenomic approaches to medication development for substance abuse with an emphasis on MA use disorders. Dr. Heinzerling is currently a co investigator with the UCLA Medication Development Unit for Stimulant Abuse, under the mentorship of Drs. Steven Shoptaw & Walter Ling. The proposal will allow Dr. Heinzerling to use the abundant educational and research resources in addiction medicine available at UCLA (S. Shoptaw & W. Ling) and Baylor (T. Kosten) and in genetics at UCLA (S. Nelson & J. McCracken) to obtain advanced training in genetics, translational research, addiction pharmacotherapy, clinical trial methodology, and responsible conduct of research that will allow him to become an independent investigator using new genomic approaches to develop medications to treat substance abuse. During the award period, Dr. Heinzerling will perform a pharmacogenomic study aimed at providing preliminary support for associations between genetic polymorphisms and two important clinical phenotypes of MA dependence, baseline frequency of MA use and treatment response to bupropion, using genotypic and phenotypic data from approximately 600 MA dependent participants undergoing screening for several NIDA-funded medication trials, including 120 participants who will be exposed to bupropion. The study will allow Dr. Heinzerling to establish the infrastructure and expertise within the UCLA Medication Development Unit required to secure R01 funding for future pharmacogenomic studies of MA dependence and response to pharmacotherapy.

描述（由申请人提供）：甲基苯丙胺（MA）的使用是美国增长最快的药物问题，对刑事司法和医疗保健系统施加压力，并带来重大的公共卫生后果，包括HIV感染。了解MA依赖性的神经生物学，分子和细胞依据的理解增加了，但没有有效的MA依赖性药物。药物基因组学研究有可能通过鉴定与MA依赖性和对治疗反应的临床表型相关的基因来加速神经生物学发现为MA依赖性的安全有效的药物疗法。这个受过指导的患者研究职业发展奖的目标是为MPH提供Keith Heinzerling，MD和MPH的培训和经验，以成为药物开发的药物开发方面的独立临床研究者，以滥用药物滥用药物，并重点介绍MA使用疾病。 Heinzerling博士目前是UCLA药物开发部门的兴奋性滥用部门的CO调查员，在DRS的指导下。 Steven Shoptaw＆Walter Ling。该提案将允许Heinzerling博士使用UCLA（S. Shoptaw＆W。Ling）和Baylor（T。Kosten）以及UCLA的遗传学（S. Nelson＆J。McCracken）使用丰富的成瘾医学教育和研究资源。）为了获得遗传学，转化研究，成瘾药物治疗，临床试验方法和负责任的研究的高级培训，这将使他能够使用新的基因组方法来开发治疗药物滥用药物的独立研究者。在奖励期间，Heinzerling博士将进行一项药物基因组学研究，旨在为遗传多态性与MA依赖的两个重要的临床表型之间的关联提供初步支持600名依赖参与者正在筛选几项NIDA资助的药物试验，其中包括将接触安非他酮的120名参与者。这项研究将使Heinzerling博士能够在UCLA药物开发单元中建立基础设施和专业知识，以确保R01资金用于MA依赖和对药物治疗的反应的未来药物基因组学研究。